Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2738

A Comparison of EQ5D Index from the UK, US, and Japan Preference Weights Model, and Mapping Algorithm from Clinical Outcomes in Patients with Rheumatoid Arthritis: Results from Golimumab Intravenous Study

9:00AM-11:00AM: Abstract Number: 2749

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results

9:00AM-11:00AM: Abstract Number: 2778

Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 2781

Absence of Effects of Filgotinib on Erythrocytes, CD8+ and NK Cells in Rheumatoid Arthritis Patients Brings Further Evidence for the JAK1 Selectivity of Filgotinib

9:00AM-11:00AM: Abstract Number: 2740

ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients

9:00AM-11:00AM: Abstract Number: 2772

Activated Memory B Cells in Rheumatoid Arthritis and Relationship to Anti-TNF Treatment

9:00AM-11:00AM: Abstract Number: 2741

An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA

9:00AM-11:00AM: Abstract Number: 2751

Assessment of the Effect of CYP3A Inhibition, CYP Induction, OATP1B Inhibition and Administration of High-Fat Meal on the Pharmacokinetics of the Potent and Selective JAK1 Inhibitor ABT-494

9:00AM-11:00AM: Abstract Number: 2728

Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting

9:00AM-11:00AM: Abstract Number: 2779

Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 2727

BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 2729

Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2758

Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2767

Comparative Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated By Serum Amyloid a

9:00AM-11:00AM: Abstract Number: 2746

Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients

9:00AM-11:00AM: Abstract Number: 2737

Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program

9:00AM-11:00AM: Abstract Number: 2777

Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan

9:00AM-11:00AM: Abstract Number: 2733

Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2753

Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study

9:00AM-11:00AM: Abstract Number: 2760

Efficacy and Safety of Sarilumab Plus MTX in Subgroups of Patients with Rheumatoid Arthritis in a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 2742

Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis

9:00AM-11:00AM: Abstract Number: 2770

Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 2755

Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2748

Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 2769

Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2763

Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar Pharmacokinetics and Pharmacodynamics Profiles in Japanese and Caucasian Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2766

Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries

9:00AM-11:00AM: Abstract Number: 2764

Head-to-Head Comparison of the Retention Rate of First Biologics in Elderly Patients with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry

9:00AM-11:00AM: Abstract Number: 2761

IL-6R Blockade with Sarilumab Plus Methotrexate Results in Changes in Clinical and Laboratory Parameters Associated with Chronic Inflammation in Patients with Moderate-to-Severe RA in a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 2771

Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry

9:00AM-11:00AM: Abstract Number: 2756

Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry

9:00AM-11:00AM: Abstract Number: 2735

Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?

9:00AM-11:00AM: Abstract Number: 2765

Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry

9:00AM-11:00AM: Abstract Number: 2759

Long-Term Survival of Biological Therapy in Rheumatoid Arthritis Elderly Patients in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2774

Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study

9:00AM-11:00AM: Abstract Number: 2724

Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2782

Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2773

Novel Mechanisms of Action for Methotrexate and Doxycycline: Prevention of Protein Adduct Formation and Free Radical Scavenging

9:00AM-11:00AM: Abstract Number: 2730

Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2731

Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry

9:00AM-11:00AM: Abstract Number: 2752

Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in a Real-World Setting

9:00AM-11:00AM: Abstract Number: 2776

Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection

9:00AM-11:00AM: Abstract Number: 2745

Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept

9:00AM-11:00AM: Abstract Number: 2736

Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2780

Relationship Between Immunogenicity, Hypersensitivity Reactions and Skin Tests Against Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2754

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of BI 655064, an Antagonistic Anti-CD40 Antibody Following Single-Dose Administration in Chinese and Japanese Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2762

Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients

9:00AM-11:00AM: Abstract Number: 2757

Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2725

Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States

9:00AM-11:00AM: Abstract Number: 2747

Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy

9:00AM-11:00AM: Abstract Number: 2739

Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study

9:00AM-11:00AM: Abstract Number: 2732

The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective

9:00AM-11:00AM: Abstract Number: 2726

The Effect of Prior Disease Duration and Prior DMARD Use on Treatment Outcomes in Patients with Early or Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2750

Tocilizumab Is Effective As 1st, 2nd and 3rd-Line Biologic DMARD in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2743

Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2768

Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2734

Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients

9:00AM-11:00AM: Abstract Number: 2775

What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?

9:00AM-11:00AM: Abstract Number: 2783

What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2744

What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].